HC Wainwright Raises United Therapeutics (NASDAQ:UTHR) Price Target to $500.00

United Therapeutics (NASDAQ:UTHR) had its price objective upped by analysts at HC Wainwright from $400.00 to $500.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 24.84% from the company’s previous close. HC Wainwright also issued estimates for United Therapeutics’ FY2027 earnings at $28.37 EPS.

Several other research firms have also recently weighed in on UTHR. Morgan Stanley cut their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Jefferies Financial Group upped their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $429.62.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $400.52 on Friday. The firm has a 50-day moving average of $307.69 and a 200-day moving average of $305.80. The stock has a market cap of $18.07 billion, a PE ratio of 15.63, a PEG ratio of 6.08 and a beta of 0.62. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the firm posted $5.85 EPS. The company’s revenue was up 11.7% compared to the same quarter last year. Equities research analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares of the company’s stock, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 118,181 shares of company stock worth $39,441,679 in the last ninety days. Insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Norges Bank acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $136,453,000. Invesco Ltd. increased its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the period. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the period. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics in the first quarter valued at approximately $101,354,000. Finally, Nuveen LLC acquired a new position in shares of United Therapeutics in the first quarter valued at approximately $83,533,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.